The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This podcast will cover additional factors to consider when evaluating older patients.
Mara Storto, MD.
Psychiatric Resident, Psychiatry Residency Training Program, New York University Langone Health, New York, NY.
Deepti Anbarasan, MD.
Clinical Assistant Professor of Psychiatry, New York University, New York, NY.
Dr. Storto and Dr. Anbarasan have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
We normally think of loperamide as an over-the-counter drug with a good safety profile. And it is, but only when used as directed. Recreational misuse of loperamide is on the rise with some dangerous collateral effects.
Edmund S. Higgins, MD.
Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC.
Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.
With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.
Talia Puzantian, PharmD, BCPPJoshua Feder, MDDrs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.